Delhi HC Bars Shilpa Medicare From Making, Selling Ruxolitinib Drugs in Patent Row
New Delhi: Shilpa Medicare has received an ex-parte ad-interim injunction order from the Delhi High Court, restraining the company and its subsidiaries from manufacturing, stockpiling, exporting, selling, or supplying pharmaceutical products containing Ruxolitinib or Ruxolitinib salts, following allegations of patent infringement.
In a regulatory filing dated December 30, 2025, made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shilpa Medicare said the order was received on December 29, 2025, and applies to the company, its material subsidiary Shilpa Pharma Lifesciences Ltd, and its wholly owned subsidiary FTF Pharma Pvt Ltd.
Shilpa Medicare Ltd., Shilpa Pharma Lifesciences Ltd.—a a material subsidiary—and FTF Pharma Pvt Ltd.—a wholly owned subsidiary—have received an ex parte ad-interim injunction Order from the Hon’ble High Court of Delhi, New Delhi restraining the Company from manufacturing, stockpiling, exporting, offering for sale and/or supplying, directly or indirectly, the pharmaceutical drug product containing the compound Ruxolitinib and/or Ruxolitinib Salts API along with any other form or compound or formulation which would amount to infringement of the Suit Patent bearing No. IN269841.
Regarding the alleged violation(s) or contravention(s), Shilpa Medicare stated that the matter pertains to an alleged patent infringement concerning IN269841, relating to Heteroaryl-Substituted Pyrrolo[2,3-b]Pyridines and Pyrrolo[2,3-b]Pyrimidines as Janus Kinase inhibitors.
Shilpa Medicare further disclosed that following the injunction, a Local Commissioner and its team visited the office premises of the Company to inspect and took relevant copies of ledgers, stock registers etc.
The Company fully cooperated with the officials during the proceedings and responded to the clarifications and details sought by them.
Clarifying the impact of the order, Shilpa Medicare stated that the product in question was used strictly for research purposes only and that there is no financial impact arising from the injunction. The company emphasized that its business operations have continued as usual and were not affected by the inspection or the court proceedings.
In terms of remedial action, the company confirmed that it has acknowledged receipt of the ex-parte ad-interim injunction order and has taken necessary steps to comply with the directions issued by the Delhi High Court. It also stated that it is evaluating its legal options, including filing appropriate responses or appeals, as advised by legal counsel.
